M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, identifies key tools in de-escalating treatment for patients with multiple myeloma.
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, speaks about some of the most used tools in patient assessment for de-escalation treatment for patients with multiple myeloma.
Transcript
What are some of the tools most frequently used to assess if a patient with multiple myeloma is eligible for de-escalation treatment?
Currently there is really no one factor yet that makes us decide if a patient is a good candidate for treatment de-escalation or not, it depends on multiple things. First of all, how long the patient has been on treatment, how the patient is doing on treatment.
Some people are on maintenance and it's not any burden to them. Some patients each clinic visit keep asking you, they cannot wait to go off treatments, basically it impacts their quality of life, etc.
And also, very importantly, how good of a response they have had, how deep the response is. And these things really assist us by MRD testing or measurable disease testing. Basically, there are different platforms, but the one that really is being used most likely in the United States is NGS testing. And we are collaborating with Adaptive, which provides us with the platform to test for us, in our patients.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More